Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by mstrmndon Jun 28, 2019 3:04pm

142 Views

Post# 29874568

RE:RE:RE:RE:RE:Naproxen-H2S (ATB-346) vs. Placebo (nothing) = Instant Money

MUGMODs I completely agree. The cost-benefit analysis from the Phase 2B GI Safety Trial will be incredible. ATB-346 alone and H2S therapy as a whole could literally save healthcare, hospitals, pharmacare programs, other insurers, and patients all around the world, billions in spending to treat NSAID induced gastrointestinal ulceration and its complications.

The best part is, the Phase 2B GI Safety results are sooo incredibly strong, that it appears the secret sauce to gut lining healing is...hydrogen sulfide

MUGMODs wrote: I'd love to go ... but have prior commitment.
Will have representation there ... my brother.

Speculating on a few other items ...
1. The 'cost of bleeding GI ulsers' report should be out soon ... hopefully. This report should cast a light on the true cost of using NSAIDs and will be a further incentive for someone to partner up on the first drug - great future sales tool.
2. Knight to make a futher play on some regional deals (eg. South America) - I'm thinking Goodman isn't done here ... but ... will be required to pay much more this time around.